OPEN

Helicobacter fennelliae Bacteremia

Three Case Reports and Literature Review

Sho Saito, MD, Mika Tsukahara, MT, Kiyofumi Ohkusu, PhD, and Hanako Kurai, MD

Abstract: *Helicobacter fennelliae* is a gram-negative, spiral bacillus that appears as thin-spread colonies on sheep blood agar and is similar to *Helicobacter cinaedi. H fennelliae* is diagnosed by genetic testing, which is not readily available in all laboratories. Therefore, *H fennelliae* bacteremia has only been reported sporadically, and little is known about its clinical characteristics.

We describe 3 cases of *H fennelliae* bacteremia with gastrointestinal symptoms, including nausea, vomiting, and diarrhea. Isolates could be differentiated from *H cinaedi* by biochemical reaction testing, including nitrate reduction and alkaline phosphatase hydrolysis.

We retrospectively reviewed 24 cases of *H fennelliae* bacteremia reported in the literature. Most of the patients had immunosuppressive backgrounds, including solid tumors, hematological malignancies, and autoimmune diseases. Although gastrointestinal symptoms were common, cellulitis was not often observed in patients with *H fennelliae* bacteremia.

Clinicians should bear in mind that *H fennelliae* may be a differential diagnosis in patients with gastrointestinal manifestations and gramnegative, spiral bacilli. In addition, biochemical reactions, such as nitrate reduction and alkaline phosphatase hydrolysis, are useful in differentiating *H fennelliae* from *H cinaedi*.

(Medicine 95(18):e3556)

Abbreviation: *H.* = *Helicobacter*.

INTRODUCTION

H elicobacter fennelliae was first described in 1985 as a new Campylobacter species isolated from asymptomatic, homosexual men with enteritis and proctitis.¹ This organism was subsequently reorganized as a Helicobacter species based on 23S rRNA hybridization studies in 1991.² Helicobacter species are gram-negative, spiral bacteria that are categorized into 2 groups: gastric Helicobacter and enterohepatic Helicobacter.³ H fennelliae is an enterohepatic Helicobacter that causes bacteremia and appears as thin-spread colonies on sheep blood agar. This organism is fastidious and difficult to culture, and its features are similar to Helicobacter cinaedi. In addition, H fennelliae is diagnosed by genetic testing, such as 16 s rRNA sequencing,

Correspondence: Sho Saito, Division of Infectious Diseases, Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan (e-mail: s.saito@scchr.jp).

DOI: 10.1097/MD.00000000003556

which is not readily available in all laboratories. Therefore, *H fennelliae* bacteremia has been reported only sporadically, and little is known about its clinical characteristics.

We report 3 cases of H fennelliae bacteremia that could be differentiated from H cinaedi by biochemical reaction testing and provide a review of the literature.

CASE PRESENTATION

Case 1

A 77-year-old Japanese female with cervical cancer and malignant pleural effusion presented at our hospital. She had a radical hysterectomy for treatment of cervical cancer 1 year prior and had received 3 courses of paclitaxel and nedaplatin. She developed bilateral lower extremity lymphedema 3 days before presentation and low back pain, nausea, and vomiting the day before. Her body temperature was 36.6 °C, heart rate was 105 beats/min, and blood pressure was 93/57 mm Hg. The physical examination revealed tenderness in the upper part of the abdomen, costovertebral angle tenderness, and pitting edema in the lower leg, but was otherwise unremarkable. Blood tests obtained on admission revealed a white blood cell count of 11,730 cells/µL with 97% neutrophils, a C-reactive protein level of 40.5 mg/dL, a blood urea nitrogen level of 58.2 mg/dL, and a creatinine level of 1.39 mg/dL. After 2 sets of blood cultures were obtained, she was treated for dehydration with 1 g of intravenous cefepime, 3 times a day. Five days later, spiral-shaped, gramnegative bacilli, a shape suggestive of Helicobacter spp, were isolated from both aerobic blood cultures. Intravenous antibiotic therapy was changed from cefepime to 2 g of ampicillin 4 times a day to treat suspected H cinaedi bacteremia. After the patient showed improvement of her general condition, intravenous ampicillin was switched to oral amoxicillin on the 12th day after admission for treatment of enteritis and bacteremia, and antibiotics were given for a total of 18 days. No recurrence was observed during the 18-month follow-up.

Case 2

A 51-year-old Japanese female with esophageal cancer, liver metastasis, and malignant pleural effusion presented at our hospital. She had received 2 courses of cisplatin and fluorouracil, and radiotherapy. Two days before hospitalization, she had developed anorexia accompanied by nausea and vomiting. Her body temperature was 36.5 °C, heart rate was 98 beats/min, blood pressure was 96/58 mm Hg, and SpO2 was 90%. The physical examination was otherwise unremarkable. Blood tests obtained on admission revealed a white blood cell count of 14,210 cells/ μ L with 90% neutrophils, a C-reactive protein level of 7.71 mg/dL, a blood urea nitrogen level of 22.0 mg/ dL, and a creatinine level of 0.88 mg/dL. Two sets of blood cultures were obtained, and 5 days later, bacteria with a shape suggestive of *Helicobacter* spp were isolated from both blood cultures. The patient was administered 1.5 g of ampicillin/

Editor: Susanna Esposito.

Received: January 5, 2016; revised: March 29, 2016; accepted: March 31, 2016.

From the Division of Infectious Diseases (SS, MT, HK), Shizuoka Cancer Center Hospital, Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan; and Department of Microbiology (KO), Tokyo Medical University, Nishishinjuku, Shinjuku-ku, Tokyo, Japan.

The authors have no funding and conflicts of interest to disclose.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ISSN: 0025-7974

sulbactam intravenously, 4 times a day. However, she died due to an underlying disease 27 days after hospital admission.

Case 3

A 74-year-old Japanese female with pancreatic cancer and lymph node metastasis, who had received 2 courses of gemcitabine and nanoparticle albumin-bound paclitaxel, was admitted to our hospital due to persistent fever and a positive blood culture. One week before hospitalization, 2 sets of blood cultures were obtained, and spiral-shaped, gram-negative bacilli were isolated from one of the blood cultures after 5 days. Her body temperature on admission was 36.4 °C, heart rate was 63 beats/min, and blood pressure was 112/50 mm Hg. She had a history of diarrhea and pasty stools. Additionally, she noted mild pain in both knees, and pitting edema in the lower leg was observed; however, the physical examination was otherwise unremarkable. Initial laboratory findings included a white blood cell count of 10,800 cells/µL with 76% neutrophils, a C-reactive protein level of 8.24 mg/dL, a blood urea nitrogen level of 16.7 mg/dL, and a creatinine level of 0.77 mg/dL. She was administered 2 g of ampicillin intravenously, 4 times a day. Ampicillin was switched to oral amoxicillin on the 4th day after intravenous treatment, and antibiotics were given for a total of 6 weeks. Her follow-up blood cultures were all negative, and no recurrence had been observed at follow-ups.

Blood culture samples were processed using the Bactec FX system (Becton, Dickinson and Company, Sparks, MD). Microaerobic cultures were performed with chocolate II agar (Kyokuto Pharmaceutical, Tokyo, Japan) and Trypto soy agar II with sheep blood (Kyokuto Pharmaceutical, Tokyo, Japan) for 6 days at 37 °C in a moist microaerobic atmosphere (5% O₂, 10% CO₂, 0% H₂, 85% N₂) generated by the TE-HER CAMPYLO INCUBA-TOR HZC-3 (Hirasawa Works, Tokyo, Japan). *H fennelliae* infection was suspected when blood cultures demonstrated thin-spread colonies and gram-negative spiral bacilli (Figures 1 and 2). The isolates were then identified by DNA sequencing of the 16S rRNA genes for *H fennelliae* and were also tested for nitrate reduction and alkaline phosphatase hydrolysis using the Api campy identification system (bioMerieux Vitek, Tokyo, Japan), which can be performed in general hospitals (Table 1).

The study protocol was approved by the institutional review board of the Shizuoka Cancer Center Hospital. The



FIGURE 1. Morphological analysis of *Helicobacter fennelliae* from blood cultures (Gram stain, magnification 1,000×).



FIGURE 2. Thin-spread colonies on Trypto soy agar II with sheep blood.

patient consent requirement was waived due to the retrospective nature of the study.

DISCUSSION

According to a growing number of studies and advances in genetic analysis, such as 16S rRNA gene sequencing, the number of reports of H fennelliae bacteremia has been steadily growing throughout the last decade. However, few reports have assessed the clinical characteristics or the treatment of patients with H fennelliae bacteremia. We describe 3 cases of H fennelliae bacteremia that were differentiated from H cinaedi by biochemical reaction testing and provide a literature review. To the best of our knowledge, this is the first review of H fennelliae bacteremia.

Clinical characteristics of *H fennelliae* bacteremia are summarized in Table 2.^{4–17} A comprehensive literature review of *H fennelliae* bacteremia revealed 24 cases documented between 1993 and 2014. These cases were reported from the United Kingdom, the United States of America, Taiwan, South Africa, and Japan. Skirrow et al first described 2 cases of *H fennelliae* bacteremia in 1993, both of which were in Asian males. Most of the patients had immunosuppressive backgrounds, including solid tumors (4 cases), hematological malignancies (3 cases), diabetes mellitus (1 case), liver diseases (3 cases), kidney diseases (3 cases), autoimmune diseases (3 cases), and organ transplantation (1 case). However, in 1 case, *H fennelliae* bacteremia occurred in a patient who had no known underlying disease. All our cases had solid tumors and had also been receiving chemotherapy as treatment.

Clinical symptoms included gastrointestinal symptoms, such as abdominal pain, diarrhea, nausea, and vomiting (7 cases);

TABLE 1. Differential Characteristics of *H fennelliae* and *H cinaedi*

Taxon	Nitrate Reduction	Alkaline Phosphatase Hydrolysis	Catalase Production	Urease Activity	
H fennelliae	_	+	+	_	
H cinaedi	+	_	+	_	

H fennelliae = Helicobacter fennelliae, H cinaedi = Helicobacter cinaedi.

Author	Year	Age, Sex	Background	Clinical Features	Diagnosis	Antimicrobials
Skirrow et al ⁴	1993	NR, male	NR	Fever	NR	NR
Kiehlbauch et al ⁵	1995	NR, male NR, female	Hepatitis NR	NR NR	NR DNA-DNA	NR NR
	1775	Titt, Tolliaio	1111		hybridization	
Hsueh et al ⁶	1999	48, male	Cirrhosis diabetes mellitus	Fever, shaking chills, drowsiness, dyspnea, hypotension	Gas chromatogram	Ampicillin/ Sulbactam+ Ceftazidime
Asahara et al ⁷	2008	NR	NR	NR	23S rRNA	NR
Omata et al ⁸	2011	60, female	SLE, femoral head osteonecrosis	Fever, lower extremity rash	NR	Imipenem
Inui et al ⁹	2011	46, female	None	Fever, abdominal pain, proctitis	NR	Ceftriaxone
Smuts and Lastovica ¹⁰	2011	NR, female	NR	Pneumonia	16S rRNA, rpoB	→Azithromycin NR
Lastovica		5, male		Diarrhea, acidosis	16S rRNA, rpoB	NR
		13, male		NR	16S rRNA, rpoB	NR
		6, female	Marasmus	Fever, gastroenteritis	16S rRNA, rpoB	NR
		8, female		Pneumonia	16S rRNA, rpoB	NR
Nishida et al ¹¹	2013	56, male	Alcoholic liver disease	Fever, headache, stiff neck meningitis	16S rRNA	Ceftriaxone
Otani et al ¹²	2013	55, female	SLE, lupus nephritis	Cellulitis	NR	Cefazolin
Nagamatsu et al ¹³	2013	73, male	Lung cancer	Fever, recurrent bacteremia	16S rRNA	Ampicillin/ Sulbactam →Cefepime →Amoxicillin+ Doxycycline
Maehara et al ¹⁴	2013	50, male	Renal transplantation	Fever, chill abdominal pain	Genetic analysis	NR
Rimbara et al ¹⁵	2013	NR	Malignant lymphoma	NR	16, 23S rRNA	NR
		NR	Malignant lymphoma	NR	16, 23S rRNA	NR
		NR	Autoimmune disease	NR	16, 23S rRNA	NR
Yoshizaki et al ¹⁶	2014	64, male	Renal failure	Recurrent bacteremia, bacterial pericarditis	Genetic analysis	Ceftriaxone →Piperacillin
Miyagi et al ¹⁷	2014	50s, male		Lymphoplasmacytic lymphoma	Fever, recurrent bacteremia	16S rRNA
Clarithromycin				lympionia	Successing	→Ceftazidime
Present case		77, female	Cervical cancer	Low back pain, nausea, vomiting	16S rRNA	Cefepime
						→Ampicillin →Amoxicillin
Present case		51, female	Esophageal cancer	Nausea, vomiting	16S rRNA	Ampicillin/ Sulbactam
Present case		74, female	Pancreatic cancer	Fever, diarrhea, arthralgia	16S rRNA	Ampicillin
						→Amoxicillin

 TABLE 2. Helicobacter fennelliae Bacteremia Case Reference

NR = not reported, SLE = systemic lupus erythematosus.

cellulitis (1 case), rash (1 case), meningitis (1 case), bacterial pericarditis (1 case), and fever (10 cases). Gastrointestinal symptoms were common; however, cellulitis was not as common in patients with *H fennelliae* bacteremia as it is in those with *H cinaedi* bacteremia.¹⁸ However, 3 cases of recurrent bacteremia have been identified in previous reports, ^{13,16,17} which were similar to those of *H cinaedi*.^{18,19} No deaths have been reported due to *H fennelliae* bacteremia in the current or previous cases.

Detailed pathophysiology of the developing *H* fennelliae infection has not yet been demonstrated. However, acute mucosal inflammation was observed in rectal biopsies from pig-tailed macaque monkeys that developed diarrhea in response to *H* fennelliae infection.²⁰ In addition, general and specific mechanisms for innate immune evasion and suppression were established from *Helicobacter* species.²¹ Further research is needed to provide information on the pathophysiology of *H* fennelliae infection.

Currently, there are no recommended guidelines for susceptibility testing or the treatment of diagnosed *H fennelliae* bacteremia. *H cinaedi*, also a gram-negative, spiral bacteria, is well known to be resistant to macrolides and quinolones.²² In recent reports, most clinicians have treated *H fennelliae* bacteremia with β -lactam antibiotics as first-line therapy: penicillin in 4 cases, cephalosporin in 6 cases, and carbapenem in 1 case.

Nitrate reduction and alkaline phosphatase hydrolysis reactions were useful in the diagnosis of H fennelliae, which has a similar morphology to H cinaedi. H fennelliae cultured on an agar plate appears as thin-spread colonies, which are difficult to distinguish from *H* cinaedi. In 1 report, the strain was misidentified as H cinaedi because the strains have similar morphologies.³ Recently, almost all strains of *H fennelliae* are identified by genetic analysis, such as 16S rRNA gene sequencing; however, such techniques can only be performed in specialized laboratories. H fennelliae demonstrate some biochemical differences from other *Helicobacter* species,²³ such as lacking urease activity and being catalase-positive, nitratenegative, indoxyl acetate hydrolysis-positive, alkaline phosphatase-positive, and gamma-glutamyl transpeptidase-negative. Tanaka et al reported that nitrate reduction and alkaline phosphatase hydrolysis may be useful in differentiating Helicobac*ter* species.²⁴ In the present cases, all 3 strains were negative for nitrate reduction, but were alkaline phosphatase-positive, and thus could be differentiated from H cinaedi. Therefore, nitrate reduction and alkaline phosphatase hydrolysis tests are useful techniques for diagnosing H fennelliae in general laboratories.

In conclusion, we describe 3 cases of *H fennelliae* bacteremia, which had caused gastrointestinal symptoms, and provide a literature review. Although gastrointestinal symptoms were common, cellulitis was not commonly observed in patients with *H fennelliae* bacteremia. Clinicians should bear in mind that *H fennelliae* may be a differential diagnosis in patients with gastrointestinal manifestations and gram-negative, spiral bacilli. In addition, biochemical reaction testing, including nitrate reduction and alkaline phosphatase hydrolysis, is useful in differentiating *H fennelliae* from *H cinaedi*.

ACKNOWLEDGMENT

The authors thank Yasuyuki Nakamura for obtaining the clinical images.

REFERENCES

1. Totten PA, Fennell CL, Tenover FC, et al. *Campylobacter cinaedi* (sp. nov.) and *Campylobacter fennelliae* (sp. nov.): two new

Campylobacter species associated with enteric disease in homosexual men. *J Infect Dis.* 1985;151:131–139.

- Vandamme P, Falsen E, Rossau R, et al. Revision of Campylobacter, Helicobacter, and Wolinella taxonomy: emendation of generic descriptions and proposal of Arcobacter gen. nov. *Int J Syst Bacteriol.* 1991;41:88–103.
- Rimbara E, Matsui M, Mori S, et al. Draft genome sequence of *Helicobacter fennelliae* strain MRY12-0050, isolated from a bacteremia patient. *Genome Announc*. 2013;1:e00512–e00513.
- Skirrow MB, Jones DM, Sutcliffe E, et al. Campylobacter bacteraemia in England and Wales, 1981–1991. *Epidemiol Infect.* 1993;110:567–573.
- Kiehlbauch JA, Brenner DJ, Cameron DN, et al. Genotypic and phenotypic characterization of *Helicobacter cinaedi* and *Helicobacter fennelliae* strains isolated from humans and animals. J Clin Microbiol. 1995;33:2940–2947.
- Hsueh PR, Teng LJ, Hung CC, et al. Septic shock due to *Helicobacter fennelliae* in a non-human immunodeficiency virusinfected heterosexual patient. J Clin Microbiol. 1999;37:2084–2086.
- Asahara M, Kawakami S, Ono Y, et al. *Helicobacter cinaedi* and *H. fennelliae* Isolated from Blood Culture [Ketuekibaiyou kara bunri sareta *Helicobacter cinaedi* to *H. fennelliae* ni kansuru kentou] [abstract P-026]. In: Program and abstracts of the 20th Annual Meeting of the Japanese Society for Clinical Microbiology. Sendai: The Japanese Society for Clinical Microbiology, *Nihon Rinsyou Biseibutugaku Zasshi*. 2008; 18:150.
- Omata M, Hirai K, Noda K, et al. *Helicobacter fennelliae* bacteremia a in systemic lupus erythematosus patient after hip replacement arthroplasty [Jinkoukokansetu-tikanjyutugo ni *Helicobacter fennelliae* haiketusyou wo kitasita systemic lupus erythematosus no itirei]. *Kanto Rheumatism.* 2011;44:152–157.
- Inui A, Uehara Y, Amari Y, et al. A case of *Helicobacter fennelliae* bacteremia in an immunocompetent patient [Kenjyoujin ni hassyousita *Helicobacter fennelliae* niyoru haiketusyou no itirei]. *Nihon Byouin Sougou Sinryou Igakukai Zasshi*. 2011;2:122–123.
- Smuts HE, Lastovica AJ. Molecular characterization of the 16S rRNA gene of *Helicobacter fennelliae* Isolated from stools and blood cultures from paediatric patients in South Africa. *J Pathog.* 2011;2011:217376.
- 11. Nishida D, Kanda K, Sato S, Shibayama H, Fukutake T. Adult case of *Helicobacter fennelliae* meningitis [*Helicobacter fennelliae* niyoru zuimakuen no seijinrei] [abstract A-32]. In: Program and abstracts of the 200th Kantokoshinetsu meeting of the Japanese Society of Neurology. Tokyo: Japanese Society of Neurology, *Rinsyou Sinkeigaku*, 2013; 53:164.
- 12. Otani K, Noda K, Hirai K, Ukichi T, Kingetsu I, kurosaka D. Four cases of spiral bacillus infection with immunosuppression therapy for collagen disease [Kougenbyou ni taisuru menekiyokuseiryouhoutyuu ni hassyou sita rasenkin kansensyou no yonrei] [abstract P3-226]. In: Program and abstracts of the 57th Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology. Kyoto: Japan College of Rheumatology, *Nihon Rheumatic Gakkai Soukai Gakujyutu Syukai Syourokusyu*, 2013:685.
- 13. Nagamatsu M, Mezaki K, Yamada K, Tojo M, Kirikae T, Ohmagari N. A case of recurrent bacteremia with *Helicobacter fennelliae* in a patient undergoing chemotherapy [Kagakuryouhoutyuu ni kurikaesi hassyousita *Helicobacter fennelliae* niyoru kinketusyou no itirei] [abstract P-038]. In: Program and abstracts of the 25th Annual Meeting of the Japanese Society for Clinical Microbiology. Nagoya: The Japanese Society for Clinical Microbiology, *Nihon Rinsyou Biseibutugaku Zasshi*, 2013; 23:254.
- Maehara C, Yoshizawa S, Aoki K, et al. A case of *Helicobacter* fennelliae bacteremia [*Helicobacter fennelliae* niyoru kinketusyou no itirei] [abstract P-039]. In: Program and abstracts of the 25th Annual

Meeting of the Japanese Society for Clinical Microbiology. Nagoya: The Japanese Society for Clinical Microbiology, *Nihon Rinsyou Biseibutugaku Zasshi*, 2013; 23:255.

- Rimbara E, Mori S, Kim H, et al. *Helicobacter cinaedi* and *Helicobacter fennelliae* transmission in a hospital from 2008 to 2012. J Clin Microbiol. 2013;51:2439–2442.
- 16. Yoshizaki M, Matsumoto K, Kanaya A, et al. Identification of *Helicobacter* species by gene analysis in a patient receiving hemodialysis [Helicobacter zoku niyoru kansensyou wo hassyousi kinsyu no idensikaiseki wo okonatta ketuekitousekikanja no nirei] [abstract P-2-605]. In: Program and abstracts of the 59th Congress of the Japanese Society for Dialysis Therapy. Kobe: The Japanese Society for Dialysis Therapy, *Nihon Touseki Igakukai Zasshi*, 2014; 47:904.
- 17. Miyagi C, Ohshiro T, Tamaki Y, Goeku C, Ohkusu K. A case of *Helicobacter fennelliae* bacteremia [Ketuekibaiyou kara *Helicobacter fennelliae* ga kensyutu sareta itirei] [abstract 038]. In: Program and abstracts of the 49th Japanese Association of Medical Technologists Congress Kyushu and Okinawa. Okinawa: The Japanese Association of Medical Technologists, *Nichiringi Kyusyusibu Igakukensa Gakkai*, 2014:98.
- Araoka H, Baba M, Kimura M, et al. Clinical characteristics of bacteremia caused by *Helicobacter cinaedi* and time required for

blood cultures to become positive. J Clin Microbiol. 2014;52: 1519–1522.

- Uckay I, Garbino J, Dietrich PY, et al. Recurrent bacteremia with *Helicobacter cinaedi*: case report and review of the literature. *BMC Infect Dis.* 2006;6:86.
- Flores BM, Fennell CL, Kuller L, et al. Experimental infection of pigtailed macaques (Macaca nemestrina) with *Campylobacter cinaedi* and *Campylobacter fennelliae*. *Infect Immun*. 1990;58:3947–3953.
- Mestrovic T, Ljubin-Sternak S, Sviben M. Potential role of enterohepatic *Helicobacter* species as a facilitating factor in the development of *Chlamydia trachomatis* proctitis. *Med Hypotheses*. 2013;81:481–483.
- Kawamura Y, Tomida J, Morita Y, et al. Clinical and bacteriological characteristics of *Helicobacter cinaedi* infection. J Infect Chemother. 2014;20:517–526.
- Fox JG, Chien CC, Dewhirst FE, et al. *Helicobacter canadensis* sp. nov. isolated from humans with diarrhea as an example of an emerging pathogen. *J Clin Microbiol.* 2000;38:2546–2549.
- Tanaka T, Goto M, Okuzumi K, et al. Isolation and identification of *Helicobacter cinaedi* and *H. cinaedi*-like organisms isolated from blood culture in practical laboratory procedures. *Kansenshogaku Zasshi.* 2007;81:700–706.